



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antimigraine Agents - Other

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis, Strength, Refills, Specialty Pharmacy.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a request for a renewal of authorization?

Yes checkbox

No checkbox

Q2. Does the patient have a history of contraindication to the requested drug?

Yes checkbox

No checkbox

Q3. Is this a request for a calcitonin gene-related peptide (CGRP) antagonist?

Yes checkbox

No checkbox

Q4. Is the requested calcitonin gene-related peptide (CGRP) antagonist prescribed by or in consultation with a neurologist OR a headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS)?

Yes checkbox

No checkbox

Q5. Is the requested drug being prescribed for the prevention of migraine?

Yes checkbox

No checkbox

Q6. Has the patient had a reduction in the average number of migraine days or headache days per month from baseline?

Yes checkbox

No checkbox

Q7. Has the patient experienced a decrease in the severity or duration of migraines from baseline?

Yes checkbox

No checkbox

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antimigraine Agents - Other

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q8. Is the patient being prescribed a dose that is consistent with Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Is the requested drug being prescribed for a diagnosis of episodic cluster headache?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Does the patient have documentation of a positive clinical response to the requested drug, as evidenced by a reduction in cluster headache frequency from baseline?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Is the patient being prescribed a dose and duration of therapy that is consistent with Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. Is this a request for an ergot alkaloid?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q13. Has the patient experienced an improvement in headache pain control or duration?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Is the patient being treated for a diagnosis that is indicated in the Food and Drug Administration (FDA) approved package insert OR a medically accepted indication?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Is the requested drug age appropriate for the patient according to Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Does the patient have a history of contraindication to the requested drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Will the patient be using the requested drug with another calcitonin gene-related peptide (CGRP) antagonist?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Does the patient have a diagnosis of migraine with or without aura confirmed according to the current International Headache Society Classification of Headache Disorders?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antimigraine Agents - Other

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q19. Does the patient have documentation of the baseline average number of migraine days and headache days per month?
Q20. Has the patient averaged four or more migraine days per month over the previous three months?
Q21. Does the patient have a history of therapeutic failure of at least one preventive drug from TWO of the following drug classes: A) beta blockers (e.g., metoprolol, propranolol, timolol), B) antidepressants (e.g., amitriptyline, venlafaxine), C) anticonvulsants (e.g., topiramate, valproic acid, divalproex)?
Q22. Does the patient have a history of a contraindication to or intolerance of all of the preventive drugs from ALL of the following drug classes: A) beta blockers (e.g., metoprolol, propranolol, timolol), B) antidepressants (e.g., amitriptyline, venlafaxine), C) anticonvulsants (e.g., topiramate, valproic acid, divalproex)?
Q23. Is this a request for a preferred calcitonin gene-related peptide (CGRP) antagonist?
Q24. Does the patient have a history of therapeutic failure, contraindication to, or intolerance of the preferred calcitonin gene-related peptide (CGRP) antagonists approved or medically accepted for the patient's diagnosis?
Q25. Does the patient have a diagnosis of episodic cluster headache confirmed according to the current International Headache Society Classification of Headache Disorders?
Q26. Does the patient have a history of therapeutic failure, contraindication to, or intolerance of at least one other preventive drug recommended by current consensus guidelines for episodic cluster headache (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society)?
Q27. Does the patient have a diagnosis of headache based on the current International Headache Society Classification of Headache Disorders?
Q28. Does the patient have a documented history of trial and failure, contraindication to, or intolerance of standard first-line abortive medications based on headache classification as recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society)?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Antimigraine Agents - Other

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q29. Additional Information:

Prescriber Signature

Date

Updated for 2020